Clinical Observation on the Treatment of Idiopathic Pulmonary Hypertension with Macitentantan
Objective To explore the horse yesterday teng treatment of idiopathic pulmonary arterial hypertension(1PAH)clinical efficacy and safety.Methods Patients diagnosed with IPAH who were hospitalized in Fuwai Cardiovascular Hospital of Yunnan Province from September 2019 to October 2022 were selected and given marxitentan monotherapy or combined with other targeted drugs.Baseline clinical data were collected before medication,and the changes of baseline clinical indicators were reviewed after 1 year of treatment.Results Among the 13 IPAH patients,there were 2 males(15.4％)and 11 females(84.6％).All of the 13 patients were treated with marictentan targeted drugs for 1 year.The results showed that the WHO cardiac function grade of the patients was improved before and after treatment(grade 2.7±0.9,grade 2.0±0.7,P=0.032).The 6-minute walking distance before and after treatment was significantly improved(6MWD)[(316.8±136.5)m,(408.3±129.1)m,P=0.002].N-terminal B-type natriuretic peptide was significantly decreased before and after treatment[(1 852.0±1 901.3)ng/L,(724.8±875.8)ng/L,P=0.0327].The mean pulmonary artery pressure decreased before and after treatment[(58.0±19.8)mmHg,(47.3±13.1)mmHg,P=0.014].The risk stratification of IPAH patients was improved before and after treatment(2.1±0.6,1.4±0.5,P=0.006).Conclusion All 13 IPAH cases were treated with marxitentan monotherapy or combined with other targeted drugs according to risk stratification.The baseline clinical indicators were improved with no significant adverse drug reactions after reexamination 1 year later.
NETL
NSTL
万方数据
